Recent news on Hycamtin

Oral and IV Hycamtin® Equally Effective for Small Cell Lung Cancer  -  25 May 2007
Cancer Consultants (press release),Researchers involved in an International Study have confirmed that the oral form of Hycamtin is as effective as the IV form for the second line palliative

NIPPON KAYAKU APPLIES TO MAKE HYCAMTIN DRUG FOR OVARIAN CANCER  -  May 14, 2007
Therapeutics Daily (subscription) (press release),...(TSE:4272) applied Friday to the Ministry of Health to add treatment of ovarian cancer to the indications for Hycamtin, a treatment for lung cancer

What Is in the Pipeline at GlaxoSmithKline?  -  Feb 25, 2007
Cancer Focus,Hycamtin, a topo-isomerase I inhibitor, is an indicated therapy for ovarian cancer first-line therapy in phase III trials with expected filing for approval

2007 Update of What is in the Oncology Pipeline at Glaxosmithkline  -  Mar 6, 2007
Cancer Focus,Hycamtin is a topo-isomerase I inhibitor indicated for use in cervical cancer, second-line therapy and has been approved Nov06.

MP in call for halt to use of anti-depressant  -  Mar 6, 2007
Scotland Courier,Dr Hudson admits that he previously had “significant involvement in a number of SB products—especially Avanda, Hycamtin and Paroxetine (aka Seroxat).�

Intraperitoneal Chemotherapy in First Line Therapy Improves ...  -  Feb 8, 2007
Cancer Consultants (press release),A recent phase II trial showed promising results with the administration of intraperitoneal Hycamtin® following Taxol® and Paraplatin® therapy.

Hycamtin® (topotecan HCl) Indication Expanded To Include Treatment ...  -  Dec 8, 2006
Medical News Today (press release),GlaxoSmithKline plc announced today that the European Medicines Agency (EMEA) has granted Marketing Authorisation for HYCAMTIN® (topotecan HCl) in

Hycamtin® Improves Survival in Patients with Relapsed Small Cell ...  -  Dec 6, 2006
Cancer Consultants (press release),To compare treatment with best supportive care (care to relieve symptoms) plus the oral chemotherapy drug Hycamtin to treatment with best supportive care

Hycamtin(R) (Topotecan HCl) Indication Expanded To Include ...  -  Dec 1, 2006
DG NewsThe expanded indication is based on phase 3 results that demonstrate a survival advantage by using Hycamtin (0.75mg/m2 days 1-3) in combination with

GlaxoSmithKline granted EU marketing approval for Hycamtin for ...  -  Dec 1, 2006
Forbes,LONDON (AFX) - GlaxoSmithKline PLC said the European Medicines Agency (EMEA) has granted marketing authorisation for its Hycamtin product in combination

GSK score EU nod for combo cervical cancer drug  -  Dec 4, 2006
Pharma Times (subscription),GlaxoSmithKline has been boosted by the news that the European Medicines Agency has granted marketing approval for the firm's Hycamtin (topotecan) to be

EU backs Glaxo combination drug for cervical cancer  -  Dec 1, 2006
ReutersL: Quote, Profile, Research) said on Friday it had won European regulatory approval to sell its Hycamtin medicine as a treatment for cervical cancer in

Rheologics Establishes Scientific Advisory Board  -  Dec 7, 2006
Genetic Engineering News (press release),Gary also held prior positions at SmithKline Beecham Pharmaceuticals in a number of capacities in sales (RMA), product management (Tagamet(R), Hycamtin(R))

Doxil® and Paraplatin® Effective for Recurrent Ovarian Cancer  -  Nov 30, 2006
Cancer Consultants (press release),The data also indicates that Doxil is more effective and more cost effective than Hycamtin® (topotecan) in patients with platinum-sensitive advanced ovarian

Pharmion Acquires Cabrellis Pharmaceuticals  -  Dec 4, 2006
Pharmaceutical Online (press release),Topotecan (Hycamtin: GlaxoSmithKline), the only single-agent chemotherapeutic agent approved in the US for the treatment of SCLC sensitive disease after

Average Increase in Price of Cancer Drugs Below CPI Trend  Oct 9, 2006
For example, the price of Hycamtin, an injectable chemotherapy for the treatment of ovarian cancer, increased 10% in 2006 while the cost of carboplatin therapy ... -Genetic Engineering News (press release), Committee for Medicinal Products for Human Use Post-authorisation ...  Oct 20, 2006
...for Human Use (CHMP) adopted a positive opinion to recommend the variation to the terms of the marketing authorisation for the medicinal product Hycamtin. ... -PharmaLive.com (press release), Meeting Highlights From The Committee For Medicinal Products For ...  Oct 20, 2006
Hycamtin (topotecan), from SmithKline Beecham Plc, received a positive opinion to include treatment, in combination with cisplatin, of patients with ... -Medical News Today (press release), GSK buys nasal strip maker for $566M  Oct 9, 2006
Tykerb represents GSK's third European oncology filing this year, following cervical cancer drug Hycamtin and leukemia drug Atriance. ... -Bizjournals.com, Enzo Biochem Appoints Gary C. Cupit, Former Novartis ...  Oct 16, 2006
He also was at SmithKline Beecham Pharmaceuticals in a number of sales capacities (RMA), product management (Tagamet®, Hycamtin®) and new product development ... -Business Wire (press release), Ovarian cancer: platinum-based therapy still the gold standard  Sep 11, 2006
There are also other drugs such as Eli Lilly's Gemzar (gemcitabine), GlaxoSmithKline's Hycamtin (topotecan) and Ortho Biotech/Schering Plough's Doxil/Caelyx ... -Pharmaceutical Business Review

Doxil®/Gemzar® Confirmed Effective for Recurrent Ovarian Cancer  Sep 1, 2006
The data also indicates that Doxil is more effective and more cost effective than Hycamtin® (topotecan) in patients with platinum-sensitive advanced ovarian ... -Cancer Consultants

Hycamtin® (topotecan HCl) Indication Expanded To Include Treatment ...  -  Dec 8, 2006
Medical News Today (press release),GlaxoSmithKline plc announced today that the European Medicines Agency (EMEA) has granted Marketing Authorisation for HYCAMTIN® (topotecan HCl) in

Hycamtin® Improves Survival in Patients with Relapsed Small Cell ...  -  Dec 6, 2006
Cancer Consultants (press release),To compare treatment with best supportive care (care to relieve symptoms) plus the oral chemotherapy drug Hycamtin to treatment with best supportive care

Hycamtin(R) (Topotecan HCl) Indication Expanded To Include ...  -  Dec 1, 2006
DG NewsThe expanded indication is based on phase 3 results that demonstrate a survival advantage by using Hycamtin (0.75mg/m2 days 1-3) in combination with

GlaxoSmithKline granted EU marketing approval for Hycamtin for ...  -  Dec 1, 2006
Forbes,LONDON (AFX) - GlaxoSmithKline PLC said the European Medicines Agency (EMEA) has granted marketing authorisation for its Hycamtin product in combination

GSK score EU nod for combo cervical cancer drug  -  Dec 4, 2006
Pharma Times (subscription),GlaxoSmithKline has been boosted by the news that the European Medicines Agency has granted marketing approval for the firm's Hycamtin (topotecan) to be

EU backs Glaxo combination drug for cervical cancer  -  Dec 1, 2006
ReutersL: Quote, Profile, Research) said on Friday it had won European regulatory approval to sell its Hycamtin medicine as a treatment for cervical cancer in

Rheologics Establishes Scientific Advisory Board  -  Dec 7, 2006
Genetic Engineering News (press release),Gary also held prior positions at SmithKline Beecham Pharmaceuticals in a number of capacities in sales (RMA), product management (Tagamet(R), Hycamtin(R))

Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to ...  -  Nov 15, 2006
Earthtimes.orgTopotecan(Hycamtin(TM): GlaxoSmithKline), the only single-agent chemotherapeutic agentapproved in the US for the treatment of SCLC sensitive disease after

Addition of Hycamtin® to Standard Therapy Does Not Improve ...  Aug 3, 2006
According to results recently published in the Journal of the National Cancer Institute, the addition of Hycamtin® (topotecan) to the standard chemotherapy ... -Cancer Consultants

Triple-Chemo Regimen No Improvement in Ovarian Cancer  Aug 1, 2006
1 -- For women with advanced ovarian cancer, adding Hycamtin (topotecan) to a standard two-drug chemotherapy regimen does not improve survival, found ... -MedPage Today

Mushroom properties give efficacy boost to cancer drugs  Aug 3, 2006
Many of the currently available anti-cancer agents are derived form natural products, Paclitaxel (Taxol), and camptothecin (Hycamtin) amongst many others. ... -DrugResearcher.com

Prehistoric Plant Intrigues New York Parkinson's Researchers  Aug 15, 2006
London-based GlaxoSmithKline Plc's ovarian cancer treatment Hycamtin is made from camptotechin, the extract from the Chinese camptotheca tree, and the US Food ... -Bloomberg

Oral Hycamtin® May Offer Alternative for Recurrent Non–small ...  Jun 28, 2006
According to results recently published in the Journal of Clinical Oncology, the oral chemotherapy agent Hycamtin® (topotecan) may provide an effective ... -Cancer Consultants

Oral Hycamtin® May Offer Oral Therapy for Recurrent Non–Small ...  Jun 30, 2006
Researchers from Europe, South Africa and Canada have reported that oral Hycamtin (topotecan) and intravenous Taxotere® (docetaxel) are of equal benefit for ... -Cancer Consultants

Hycamtin® Approved for Advanced Cervical Cancer  Jun 30, 2006
GlaxoSmithKline’s chemotherapy agent Hycamtin (topotecan) has received FDA approval for an expanded indication to include treatment of recurrent cervical ... -Cancer Consultants

Supplemental New Drug Application Accepted for Hycamtin® in ...  Jun 30, 2006
US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for GlaxoSmithKline’s chemotherapy agent Hycamtin (topotecan HCL ... -Cancer Consultants

Doxil Receives Full FDA Approval  Jun 30, 2006
...the phase III study, 239 patients with recurrent epithelial ovarian cancer received Doxil® 50mg/m2 every 28 days and 235 received Hycamtin® (topotecan HCI ... -Cancer Consultants

Drug Makers Eye New Markets For Old Products  Jul 7, 2006
Among the fast-track approvals this year was expanded use of Glaxo's Hycamtin to treat advanced cervical cancer, in combination with Cisplatin. ... -Investor's Business Daily (subscription)

New vaccine fights cervical cancers  Jul 3, 2006
The FDA recently announced the drug hycamtin, which is already being used to fight ovarian and lung cancers, can be used to treat late-state cervical cancer ... -News 14 Carolina

FDA Approves New Combination Therapy for Cervical Cancer  Jun 21, 2006
Summary: The US Food and Drug Administration has approved the use of topotecan (Hycamtin) along with cisplatin for the treatment of women who have very ... -ACS News Center

Researchers Stop Tumor Growth in Mice, Ready to Join Others in ...  Jul 5, 2006
This week it approved a combination of Hycamtin (topotecan hydrochloride) and cisplatin for use as the first drug treatment for women with late-stage cancer of ... -SeniorJournal.com



Hycamtin® More Convenient than Etoposide in Small Cell Lung ...  May 5, 2006
According to results recently published in the Journal of Clinical Oncology, the chemotherapy agent Hycamtin® (topotecan) taken orally in the pill form plus ... - Cancer Consultants

Hana Biosciences Completes Licensing of Three Targeted Cancer Drug ...  May 8, 2006
Topotecan (Hycamtin(R); GlaxoSmithKline), a topoisomerase I inhibitor, is approved for use in relapsed small-cell lung cancer and in relapsed ovarian cancer ... - Genetic Engineering News





Hana Biosciences to License Three Targeted Cancer Drug Candidates ...  Mar 17, 2006
Topotecan (Hycamtin(R); GlaxoSmithKline), a topoisomerase I inhibitor, is approved for use in relapsed small-cell lung cancer and in relapsed ovarian cancer ... - Genetic Engineering News

Hana Paying Up To $42M For Inex’s Cancer Drugs  Mar 17, 2006
Topotecan, marketed under the name Hycamtin, also from GSK, is a topoisomerase I inhibitor approved for use in relapsed small-cell lung cancer and relapsed ... - BioWorld Online (subscription)

IV HYCAMTIN® Receives European Marketing Approval As Treatment ...  Feb 2, 2006
GlaxoSmithKline (GSK) announced that the European Commission (EC) has granted Marketing Authorisation for HYCAMTIN® (topotecan powder for concentrate for ... - Medical News Today

EU approves Glaxo drug Hycamtin for lung cancer  Jan 31, 2006
LONDON (Reuters) - The European Commission has given approval for GlaxoSmithKline Plc's Hycamtin drug to be used as a treatment for small cell lung cancer ... - Reuters

GSK's lung cancer drug Hycamtin gets European OK  Feb 1, 2006
LONDON (AFX) - GlaxoSmithKline PLC's treatment for patients with relapsed small cell lung cancer (SCLC) Hycamtin has received marketing approval from European ... - Forbes

IV Hycamtin Receives European Marketing Approval as Treatment for ...  Feb 1, 2006
1, 2006 -- GlaxoSmithKline (GSK) today announced that the European Commission (EC) has granted Marketing Authorisation for Hycamtin® (topotecan powder for ... - DG News

GSK Impact Limited From Hycamtin News >GSK  Feb 1, 2006
1036 GMT [Dow Jones] GlaxoSmithKline's (GSK) EC approval for Hycamtin is good news but won't have much impact on the stock, says Navid Malik of Collins Stewart ... - New Ratings

GlaxoSmithKline launches diabetes and cancer drugs  Feb 1, 2006
Glaxo drug Hycamtin is found to be effective in improving the quality of life in patients with cancer and is also found to increase the survival rate. ... - MedIndia

GSK drug approved in Europe for lung cancer  Feb 3, 2006
GlaxoSmithKline's anticancer drug, Hycamtin, has been approved by European regulators for the treatment of patients with relapsed small cell lung cancer for ... - Pharmaceutical Business Review

Glaxo wins approvals for drugs  Feb 1, 2006
...said it was launching Avandaryl, a two-in-one diabetes pill, in the United States and had been given a green light in Europe to market Hycamtin -- already used ... - Scotsman

GlaxoSmithKline announces approval of two drugs  Feb 1, 2006
British pharmaceutical group GlaxoSmithKline said that its lung cancer treatment Hycamtin had received marketing approval from European medicine regulators. ... - TODAYonline

Business news in brief  Feb 2, 2006
GlaxoSmithKline PLC's cancer drug Hycamtin, manufactured in Upper Merion, received approval from the European Union for use against small-cell lung cancer. ... - Philadelphia Inquirer

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional